Novartis CEO Circumspect About Biotech Bargains
As Renowned Analyst Ronny Gal Jumps Aboard
Executive Summary
Vas Narasimhan tells Scrip that a return to sensible valuations of biotechs could lead to increased deal-making but cautions that a number of those companies that went public "may not have been mature enough with their science” and their true value remains unclear.
You may also be interested in...
Novartis To Cut 8,000 Jobs In Global Restructure
CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.
Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters
Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.